Ticagrelor effectiveness overestimated by VASP index: platelet inhibition by ticagrelor versus prasugrel in acute coronary syndrome patients according to platelet function tests

Int J Cardiol. 2014 Sep 20;176(2):557-9. doi: 10.1016/j.ijcard.2014.07.019. Epub 2014 Jul 12.

Authors

Jean-Guillaume Dillinger¹, Stephane Manzo Silberman², Claire Bal dit Sollier³, Myriam Amsallem², Georgios Sideris², Sebastian Voicu², Patrick Henry², Ludovic Drouet³

Affiliations

¹ Department of Cardiology, Inserm U942, Lariboisiere Hospital, AP-HP, Paris Diderot University, Paris, France. Electronic address: jean-guillaume.dillinger@lrb.aphp.fr.
² Department of Cardiology, Inserm U942, Lariboisiere Hospital, AP-HP, Paris Diderot University, Paris, France.
³ Angio-hematology and IVS, Lariboisiere Hospital, AP-HP, Paris Diderot University, Paris, France.

PMID: 25074556
DOI: 10.1016/j.ijcard.2014.07.019

No abstract available

Keywords: ADP receptor blockers; Acute coronary syndrome; Aggregation; Platelets; Prasugrel; Ticagrelor.

Publication types

Comparative Study
Letter

MeSH terms

Acute Coronary Syndrome / blood*
Acute Coronary Syndrome / drug therapy*
Adenosine / analogs & derivatives*
Adenosine / therapeutic use
Humans
Male
Middle Aged
Piperazines / therapeutic use*
Platelet Aggregation Inhibitors / therapeutic use*
Platelet Function Tests / methods
Prasugrel Hydrochloride
Prospective Studies
Purinergic P2Y Receptor Antagonists / therapeutic use*
Thiophenes / therapeutic use*
Ticagrelor
Treatment Outcome

Substances

Piperazines
Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Thiophenes
Prasugrel Hydrochloride
Ticagrelor
Adenosine